Furthermore, administration of the VIP receptor antagonist VIP6–28 into the knee joint of rats with monoiodacetate-induced arthritis was able to reduce this pain behavior, thereby showing for the first time that peripheral application of VIP causes increased knee joint allodynia and secondary hyperalgesia. The gene discussed is VIP; the disease is arthritic joint disease.